Orlando Magic: Report from the 57th meeting of the American Society of Haematology, 5-7 December 2015, Orlando, USA

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The 57th American Society of Haematology (ASH) meeting held in Orlando, FL was certainly the year when myeloma management changed for good, with a plethora of newly Food and Drug Administration (FDA)-approved drugs showing impressive outcome improvements and the introduction of new techniques for disease monitoring. Also, chimeric antigen receptor (CAR) T cells continued their triumphal march, consolidating their success in lymphoma and chronic lymhocytic leukaemia (CLL) and venturing into new fields such as again multiple myeloma. Some experimental drugs showed long-awaited results (midostaurin in FLT3-mutated acute myeloid leukaemia (AML)) and some brand new drugs showed promising results in the clinic after extensive preclinical studies, such as those targeting new epigenetic factors (histone methyltransferases) and apoptosis.

Original languageEnglish
Article number612
Journalecancermedicalscience
Volume10
DOIs
Publication statusPublished - Jan 14 2016

Fingerprint

Magic
Hematology
4'-N-benzoylstaurosporine
Pharmaceutical Preparations
United States Food and Drug Administration
T-Cell Antigen Receptor
Multiple Myeloma
Acute Myeloid Leukemia
Epigenomics
Lymphoma
Leukemia
Apoptosis

Keywords

  • Leukemia
  • Lymphoma
  • Myeloma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{daf1c06a04da461db60e636b0e6f8a95,
title = "Orlando Magic: Report from the 57th meeting of the American Society of Haematology, 5-7 December 2015, Orlando, USA",
abstract = "The 57th American Society of Haematology (ASH) meeting held in Orlando, FL was certainly the year when myeloma management changed for good, with a plethora of newly Food and Drug Administration (FDA)-approved drugs showing impressive outcome improvements and the introduction of new techniques for disease monitoring. Also, chimeric antigen receptor (CAR) T cells continued their triumphal march, consolidating their success in lymphoma and chronic lymhocytic leukaemia (CLL) and venturing into new fields such as again multiple myeloma. Some experimental drugs showed long-awaited results (midostaurin in FLT3-mutated acute myeloid leukaemia (AML)) and some brand new drugs showed promising results in the clinic after extensive preclinical studies, such as those targeting new epigenetic factors (histone methyltransferases) and apoptosis.",
keywords = "Leukemia, Lymphoma, Myeloma",
author = "Luca Mazzarella",
year = "2016",
month = "1",
day = "14",
doi = "10.3332/ecancer.2016.612",
language = "English",
volume = "10",
journal = "ecancermedicalscience",
issn = "1754-6605",
publisher = "Cancer Intellilgence",

}

TY - JOUR

T1 - Orlando Magic

T2 - Report from the 57th meeting of the American Society of Haematology, 5-7 December 2015, Orlando, USA

AU - Mazzarella, Luca

PY - 2016/1/14

Y1 - 2016/1/14

N2 - The 57th American Society of Haematology (ASH) meeting held in Orlando, FL was certainly the year when myeloma management changed for good, with a plethora of newly Food and Drug Administration (FDA)-approved drugs showing impressive outcome improvements and the introduction of new techniques for disease monitoring. Also, chimeric antigen receptor (CAR) T cells continued their triumphal march, consolidating their success in lymphoma and chronic lymhocytic leukaemia (CLL) and venturing into new fields such as again multiple myeloma. Some experimental drugs showed long-awaited results (midostaurin in FLT3-mutated acute myeloid leukaemia (AML)) and some brand new drugs showed promising results in the clinic after extensive preclinical studies, such as those targeting new epigenetic factors (histone methyltransferases) and apoptosis.

AB - The 57th American Society of Haematology (ASH) meeting held in Orlando, FL was certainly the year when myeloma management changed for good, with a plethora of newly Food and Drug Administration (FDA)-approved drugs showing impressive outcome improvements and the introduction of new techniques for disease monitoring. Also, chimeric antigen receptor (CAR) T cells continued their triumphal march, consolidating their success in lymphoma and chronic lymhocytic leukaemia (CLL) and venturing into new fields such as again multiple myeloma. Some experimental drugs showed long-awaited results (midostaurin in FLT3-mutated acute myeloid leukaemia (AML)) and some brand new drugs showed promising results in the clinic after extensive preclinical studies, such as those targeting new epigenetic factors (histone methyltransferases) and apoptosis.

KW - Leukemia

KW - Lymphoma

KW - Myeloma

UR - http://www.scopus.com/inward/record.url?scp=84960532908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960532908&partnerID=8YFLogxK

U2 - 10.3332/ecancer.2016.612

DO - 10.3332/ecancer.2016.612

M3 - Article

AN - SCOPUS:84960532908

VL - 10

JO - ecancermedicalscience

JF - ecancermedicalscience

SN - 1754-6605

M1 - 612

ER -